Keep the sick from harm in spontaneous bacterial peritonitis: Dose of beta blockers matters

Journal of Hepatology

Volumn 64, Issue 6, 2016, Pages 1455-1456

  Madsen, Bjørn Stæhr ^a   Nielsen, Kristina Fruerlund ^a   Fialla, Annette Dam ^a   Krag, Aleksander ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

ACUTE ON CHRONIC LIVER FAILURE; BACTERIAL PERITONITIS; DOSE RESPONSE; HEPATORENAL SYNDROME; HUMAN; LETTER; LIVER CIRRHOSIS; LOW DRUG DOSE; PRIORITY JOURNAL; THERAPY EFFECT; ASCITES; ASCITES FLUID; BACTERIAL INFECTION; PERITONITIS;

ADRENERGIC BETA-ANTAGONISTS; ASCITES; ASCITIC FLUID; BACTERIAL INFECTIONS; HUMANS; LIVER CIRRHOSIS; PERITONITIS;

EID: 84968761507     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.01.031     Document Type: Letter

References (6)

1. A. Krag, and B.S. Madsen To block, or not to block in advanced cirrhosis and ascites: that is the question Gut 64 2015 1015 1017
2. H. Markel "I swear by Apollo" - on taking the Hippocratic oath N Engl J Med 350 2004 2026 2029
3. R.P. Mookerjee, M. Pavesi, K.L. Thomsen, G. Mehta, J. Macnaughtan, F. Bendtsen, and et al. Treatment with non-selective beta-blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure J Hepatol 64 2016 574 582
4. L. Bossen, A. Krag, H. Vilstrup, H. Watson, and P. Jepsen Non-selective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post hoc analysis of three RCTs with 1198 patients Hepatology 2015 PubMed PMID: 26599983. Epub 2015/11/26
5. L. Ruiz-del-Arbol, J. Urman, J. Fernández, M. González, M. Navasa, A. Monescillo, and et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis Hepatology 38 2003 1210 1218
6. M. Mandorfer, S. Bota, P. Schwabl, T. Bucsics, N. Pfisterer, M. Kuzik, and et al. Nonselective β blockers increase risk of hepatorenal syndrome and deaths in patients with cirrhosis and spontaneous bacterial peritonitis Gastroenterology 146 2014 1680 1690